CTI Biopharma ROE 2025

Mis teeb CTI Biopharma?

CTI Biopharma Corp is a biopharmaceutical company focused on the development of therapies for the treatment of cancer and other serious diseases. The company was founded in 1991 in Seattle, USA, and has been listed on the NASDAQ stock exchange since 1997. History: The history of CTI Biopharma Corp dates back to 1996 when the company launched its first product, a treatment for chronic myeloid leukemia. Since then, the company has continuously evolved and grown through the acquisition of other companies. In 2014, CTI Biopharma Corp merged with the French companies Cell Therapeutics, and in 2015, it acquired the Italian company Chroma Therapeutics. Business model: CTI Biopharma Corp's business model focuses on the development and commercialization of cancer therapies. The company utilizes its expertise in biology, chemistry, and medicine to develop innovative therapies that target specific molecular targets in tumors. The therapies are developed and produced by CTI Biopharma Corp itself before being distributed by doctors and healthcare facilities. Different divisions: The different divisions of CTI Biopharma Corp focus on various areas of cancer research. The "Hematology" division investigates the treatment of blood diseases such as leukemia and lymphomas. "Oncology," on the other hand, deals with the treatment of solid tumors such as breast cancer and lung cancer. Additionally, CTI Biopharma Corp also works in the field of "Toxicology" by studying the compatibility of medications and their effects on the immune system. Products: CTI Biopharma Corp offers a variety of products, but its flagship product Pixuvri is considered the most outstanding. Pixuvri is a chemotherapy drug used for the treatment of aggressive B-cell non-Hodgkin lymphomas (NHL). The drug is already approved in Europe, where it has been marketed since 2012. Pixuvri is currently under evaluation by the Food and Drug Administration (FDA) for potential introduction into the US market. Another product from CTI Biopharma Corp is Pacritinib, a tablet form used for the treatment of myelofibrosis. Conclusion: CTI Biopharma Corp has specialized in the development of drugs for the treatment of cancer and other diseases over the years. The company has focused on different divisions such as oncology and toxicology and offers a variety of products, including Pixuvri and Pacritinib. The acquisition of Chroma Therapeutics and Cell Therapeutics further highlights CTI Biopharma Corp's expansion strategy. CTI Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.